Seeking Alpha is a stock market news and financial analysis website, including free earnings call transcripts, investment ideas and ETF & stock research written by finance experts. Ryan Pollock recently initiated coverage on International Stem Cell Corporation (ISCO).  Although the views and opinions are Mr. Pollock’s own and not necessarily those of ISCO, we thought you would be interested in his insights about our company.

To read the complete article 3 Contenders To Be The First Profitable Stem Cell Company, please click HERE

Excerpt "The second company is International Stem Cell Corporation (ISCO.OB). ISCO uses a technique called parthenogenesis, which creates stem cells from unfertilized oocytes. What is interesting and intriguing about ISCO is the strategy it is using. Instead of going after a disease and clinical trials procedure first, ISCO instead is focused on cosmetics, namely a day and night skin cream combo where stem cells are an active ingredient to rejuvenate skin cells. FDA approval is not required for this product and is already on the market in a limited basis.

On the company’s last quarterly conference call it expected to sell a thousand bottles in a limited launch. Instead, the company sold seven thousand bottles. That is the good news. The bad news is that ISCO cannot sell the product again until sometime in the third quarter as it underestimated demand and the cells needed for the product take two to three months to grow. Now that ISCO knows more about the demand to expect for the product, there should hopefully be no more gaps in product production and could turn profitable within the next three to five quarters in my opinion. With a profitable cosmetic line the company then plans to fund therapeutic research and future clinical trials for liver diseases, Parkinson’s and eye diseases."